{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:19Z","timestamp":1791476059598,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, the use of interleukin (IL) 23 inhibitors in the treatment of psoriatic arthritis (PsA) has been the subject of much research. By specifically binding to the p19 subunit of IL-23, IL-23 inhibitors block downstream signaling pathways and inhibit inflammatory responses. The objective of this study was to assess the clinical efficacy and safety of IL-23 inhibitors in the treatment of PsA. PubMed, Web of Science, Cochrane Library, and EMBASE databases were searched from the time of conception to June 2022 for randomized controlled trials (RCTs) investigating the use of IL-23 in PsA therapy. The main outcome of interest was the American College of Rheumatology 20 (ACR20) response rate at week 24. We included six RCTs (3 studies on guselkumab, 2 on risankizumab, and 1 on tildrakizumab) with a total of 2971 PsA patients in our meta-analysis. We found that the IL-23 inhibitor group showed a significantly higher ACR20 response rate compared to the placebo group (relative risk = 1.74, 95% confidence interval: 1.57\u20131.92; <jats:italic>P<\/jats:italic> &lt; 0.001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 40%). There was no statistical difference in the risk of adverse events (<jats:italic>P<\/jats:italic> = 0.07) and serious adverse events (<jats:italic>P<\/jats:italic> = 0.20) between the IL-23 inhibitor and placebo groups. Notably, the rate of elevated transaminases in the IL-23 inhibitor group was higher than the placebo group (relative risk = 1.69; 95%CI 1.29\u20132.23; <jats:italic>P<\/jats:italic> &lt; 0.001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 24%). In the treatment of PsA, IL-23 inhibitors significantly outperform placebo intervention while maintaining a favorable safety profile.<\/jats:p>","DOI":"10.1007\/s12026-023-09366-4","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T15:04:10Z","timestamp":1677078250000},"page":"505-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials"],"prefix":"10.1007","volume":"71","author":[{"given":"Xiaojing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Shentu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijia","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-5650","authenticated-orcid":false,"given":"Haowei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"1","key":"9366_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251\u201365.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"9366_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370. https:\/\/doi.org\/10.1056\/NEJMra1505557.","journal-title":"N Engl J Med."},{"key":"9366_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"A-M Orbai","year":"2017","unstructured":"Orbai A-M, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76:673\u201380. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210242.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","volume":"76","author":"LE Kristensen","year":"2017","unstructured":"Kristensen LE, J\u00f8rgensen TS, Christensen R, Gudbergsen H, Dreyer L, Ballegaard C, Jacobsson LTH, Strand V, Mease PJ, Kjellberg J. Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76:1495\u2013501. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210579.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR5","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s10067-018-4187-y","volume":"37","author":"JF Merola","year":"2018","unstructured":"Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol. 2018;37:2751\u201361. https:\/\/doi.org\/10.1007\/s10067-018-4187-y.","journal-title":"Clin Rheumatol."},{"key":"9366_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:351\u201360. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.05.010.","journal-title":"Semin Arthritis Rheum."},{"key":"9366_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4.","journal-title":"Lancet."},{"key":"9366_CR8","doi-asserted-by":"publisher","first-page":"108536","DOI":"10.1016\/j.clim.2020.108536","volume":"220","author":"A Toussi","year":"2020","unstructured":"Toussi A, Maverakis N, Le ST, Sarkar S, Raychaudhuri SK, Raychaudhuri SP. Updated therapies for the management of Psoriatic Arthritis. Clin Immunol. 2020;220:108536. https:\/\/doi.org\/10.1016\/j.clim.2020.108536.","journal-title":"Clin Immunol."},{"key":"9366_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14712598.2021.1938538","volume":"22","author":"R Mohanakrishnan","year":"2022","unstructured":"Mohanakrishnan R, Beier S, Deodhar A. IL-23 inhibition for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2022;22:59\u201365. https:\/\/doi.org\/10.1080\/14712598.2021.1938538.","journal-title":"Expert Opin Biol Ther."},{"key":"9366_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jdv.16073","volume":"34","author":"ND Loft","year":"2020","unstructured":"Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34:1151\u201360. https:\/\/doi.org\/10.1111\/jdv.16073.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"9366_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","volume":"60","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, Chakravarty SD, Parackal A, Karyekar CS, Nair S, Boehncke WH, Ritchlin C. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60:2109\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/keab119.","journal-title":"Rheumatology (Oxford)."},{"key":"9366_CR12","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"BMJ."},{"key":"9366_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V. American College of RheumatologyPreliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727\u201335. https:\/\/doi.org\/10.1002\/art.1780380602.","journal-title":"Arthritis Rheum."},{"key":"9366_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ."},{"key":"9366_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ."},{"key":"9366_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"10136","key":"9366_CR17","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","volume":"391","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Gottlieb AB, Boehncke W-H, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC, Aelion J, Amarelo-Ramos J, Balsa A, Berghea F, Brzezicki J, Burnette M, Fretzin S, Garc\u00cdA-Carazo S, Gladstein G, Gomez-Reino J, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. 2018;391(10136):2213\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)30952-8.","journal-title":"The Lancet."},{"key":"9366_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","journal-title":"Lancet."},{"key":"9366_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, Noel W, Schett G, McInnes IB. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81:359\u201369. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220991.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81:225\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221019.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A Ostor","year":"2022","unstructured":"Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Alperovich G, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Kivitz A. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81:351\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221048.","journal-title":"Ann Rheum Dis"},{"key":"9366_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80:1147\u201357. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219014.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4049\/jimmunol.1003986","volume":"187","author":"IE Adamopoulos","year":"2011","unstructured":"Adamopoulos IE, Tessmer M, Chao C-C, Adda S, Gorman D, Petro M, Chou C-C, Pierce RH, Yao W, Lane NE, Laface D, Bowman EP. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 2011;187:951\u20139.","journal-title":"J Immunol."},{"key":"9366_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, Prinz JC. The role of IL-23 and the IL-23\/T 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616\u201326. https:\/\/doi.org\/10.1111\/jdv.14433.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"9366_CR26","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","volume":"76","author":"SK Raychaudhuri","year":"2017","unstructured":"Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017;76:e36. https:\/\/doi.org\/10.1136\/annrheumdis-2016-211046.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496\u2013502.","journal-title":"Autoimmun Rev"},{"issue":"4-5","key":"9366_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"20","author":"K Bunte","year":"2019","unstructured":"Bunte K, Beikler T. Th17 Cells and the IL-23\/IL-17 Axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20(4-5):496\u2013502. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.050.","journal-title":"Int J Mol Sci."},{"key":"9366_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","volume":"67","author":"GE Fragoulis","year":"2016","unstructured":"Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337\u201353. https:\/\/doi.org\/10.1146\/annurev-med-051914-021944.","journal-title":"Annu Rev Med."},{"key":"9366_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386\u2019","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386\u2019.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395:1496\u2013505. https:\/\/doi.org\/10.1016\/S0140-6736(20)30564-X.","journal-title":"Lancet."},{"key":"9366_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J, Schett G. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48:632\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.011.","journal-title":"Semin Arthritis Rheum."},{"key":"9366_CR33","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1084\/jem.20030896","volume":"198","author":"CA Murphy","year":"2003","unstructured":"Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951\u20137.","journal-title":"J Exp Med."},{"key":"9366_CR34","doi-asserted-by":"publisher","first-page":"13466","DOI":"10.1038\/ncomms13466","volume":"7","author":"P Kulig","year":"2016","unstructured":"Kulig P, Musiol S, Freiberger SN, Schreiner B, Gy\u00fclveszi G, Russo G, Pantelyushin S, Kishihara K, Alessandrini F, K\u00fcndig T, Sallusto F, Hofbauer GFL, Haak S, Becher B. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466. https:\/\/doi.org\/10.1038\/ncomms13466.","journal-title":"Nat Commun."},{"key":"9366_CR35","doi-asserted-by":"publisher","first-page":"eabg9012","DOI":"10.1126\/sciimmunol.abg9012","volume":"6","author":"P Zwicky","year":"2021","unstructured":"Zwicky P, Ingelfinger F, Silva de Melo BM, Ruchti F, Sch\u00e4rli S, Puertas N, Lutz M, Phan TS, K\u00fcndig TM, Levesque MP, Maul J-T, Schlapbach C, LeibundGut-Landmann S, Mundt S, Becher B. IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. Sci Immunol. 2021;6:eabg9012. https:\/\/doi.org\/10.1126\/sciimmunol.abg9012.","journal-title":"Sci Immunol."},{"issue":"2022","key":"9366_CR36","first-page":"465","volume":"18","author":"LC Coates","year":"2021","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernandez-Avila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, et al. G.T.R.d. subcommittees, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis. Nat Rev Rheumatol. 2021;18(2022):465\u201379.","journal-title":"Nat Rev Rheumatol."},{"issue":"2020","key":"9366_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2019","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewe RBM, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2019;79(2020):700\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159.","journal-title":"Ann Rheum Dis."},{"key":"9366_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3899\/jrheum.201532","volume":"48","author":"P Rahman","year":"2021","unstructured":"Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB. Pooled Safety Results through 1 year of 2 phase III trials of guselkumab in patients with psoriatic arthritis. J Rheumatol. 2021;48:1815\u201323. https:\/\/doi.org\/10.3899\/jrheum.201532.","journal-title":"J Rheumatol."},{"issue":"9","key":"9366_CR39","doi-asserted-by":"publisher","first-page":"ftw111","DOI":"10.1093\/femspd\/ftw111","volume":"74","author":"M Valeri","year":"2016","unstructured":"Valeri M, Raffatellu M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74(9):ftw111. https:\/\/doi.org\/10.1093\/femspd\/ftw111.","journal-title":"Pathog Dis."}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-023-09366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-023-09366-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-023-09366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T07:27:41Z","timestamp":1691998061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-023-09366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["9366"],"URL":"https:\/\/doi.org\/10.1007\/s12026-023-09366-4","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}